$ETNB
89bio, Inc.

2020 Q2 Form 10-Q Financial Statement

#000156459020040062 Filed on August 13, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q2 2018 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.230M $830.0K $720.0K
YoY Change 289.16%
% of Gross Profit
Research & Development $8.443M $3.165M $3.690M
YoY Change 166.76%
% of Gross Profit
Depreciation & Amortization $20.00K $10.00K $10.00K
YoY Change 100.0%
% of Gross Profit
Operating Expenses $11.67M $3.999M $4.410M
YoY Change 191.9%
Operating Profit $11.67M $3.999M -$4.408M
YoY Change 191.9% -157.39%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $98.00K $10.97M -$200.0K
YoY Change -99.11%
Pretax Income -$11.77M -$14.97M -$4.610M
YoY Change -21.35%
Income Tax $0.00 $6.000K $30.00K
% Of Pretax Income
Net Earnings -$11.77M -$14.97M -$4.638M
YoY Change -21.39% 103.08%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$852.9K -$1.227M -$384.7K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q2 2019 Q2 2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $73.90M $21.90M
YoY Change 237.44%
Cash & Equivalents $68.20M $21.92M $11.23M
Short-Term Investments $5.700M
Other Short-Term Assets $1.400M $100.0K
YoY Change 1300.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $75.30M $22.00M $11.32M
YoY Change 242.27%
LONG-TERM ASSETS
Property, Plant & Equipment $200.0K $0.00 $33.00K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.080M $300.0K
YoY Change 260.0%
Total Long-Term Assets $1.300M $300.0K $53.00K
YoY Change 333.33%
TOTAL ASSETS
Total Short-Term Assets $75.30M $22.00M $11.32M
Total Long-Term Assets $1.300M $300.0K $53.00K
Total Assets $76.60M $22.30M $11.37M
YoY Change 243.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.100M $1.000M $1.509M
YoY Change 210.0%
Accrued Expenses $3.700M $2.700M $1.173M
YoY Change 37.04%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.791M $9.500M $4.353M
YoY Change -28.52%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $6.791M $9.500M $4.353M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $6.800M $9.500M
YoY Change -28.42%
SHAREHOLDERS EQUITY
Retained Earnings -$95.91M -$16.18M
YoY Change
Common Stock $165.7M $119.0K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $69.77M -$35.36M -$16.06M
YoY Change
Total Liabilities & Shareholders Equity $76.56M $22.30M $11.37M
YoY Change 243.33%

Cashflow Statement

Concept 2020 Q2 2019 Q2 2018 Q4
OPERATING ACTIVITIES
Net Income -$11.77M -$14.97M -$4.638M
YoY Change -21.39% 103.08%
Depreciation, Depletion And Amortization $20.00K $10.00K $10.00K
YoY Change 100.0%
Cash From Operating Activities -$11.53M -$3.960M -$3.290M
YoY Change 191.16% -40.36%
INVESTING ACTIVITIES
Capital Expenditures -$50.00K -$20.00K $0.00
YoY Change 150.0% -33.33%
Acquisitions
YoY Change
Other Investing Activities -$5.700M
YoY Change
Cash From Investing Activities -$5.750M -$20.00K $0.00
YoY Change 28650.0% -33.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -70.00K 18.84M 9.000M
YoY Change -100.37% 27.56%
NET CHANGE
Cash From Operating Activities -11.53M -3.960M -3.290M
Cash From Investing Activities -5.750M -20.00K 0.000
Cash From Financing Activities -70.00K 18.84M 9.000M
Net Change In Cash -17.35M 14.86M 5.710M
YoY Change -216.76% 83.46%
FREE CASH FLOW
Cash From Operating Activities -$11.53M -$3.960M -$3.290M
Capital Expenditures -$50.00K -$20.00K $0.00
Free Cash Flow -$11.48M -$3.940M -$3.290M
YoY Change 191.37% -40.39%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-95911000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3230000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
11673000
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
98000
CY2020Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-11771000
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
6000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-11771000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-14973000
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
0.85
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
24.50
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
1.62
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
13797356
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
9000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
493000
CY2020Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
75000
CY2020Q2 etnb Issuance Of Common Stock Warrant In Connection With Term Loan Facility
IssuanceOfCommonStockWarrantInConnectionWithTermLoanFacility
634000
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
910000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
35000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-4439000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-20461000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
76000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
-35358000
us-gaap Profit Loss
ProfitLoss
-22315000
us-gaap Profit Loss
ProfitLoss
-19412000
us-gaap Depreciation
Depreciation
29000
us-gaap Depreciation
Depreciation
7000
us-gaap Share Based Compensation
ShareBasedCompensation
1403000
us-gaap Share Based Compensation
ShareBasedCompensation
111000
etnb Deferred Tax Assets
DeferredTaxAssets
50000
etnb Revaluation Of Convertible Preferred Stock Liability
RevaluationOfConvertiblePreferredStockLiability
10511000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
77000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-595000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
36000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2123000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-541000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1189000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
11673000
CY2020Q2 us-gaap Short Term Investments
ShortTermInvestments
5697000
CY2020Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1080000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
14000
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
14000
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
6791000
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-14967000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
10552000
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
611226
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
13793544
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-10544000
CY2020Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
165668000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
89944000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-73596000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
163526000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6154000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1357000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
95553000
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3165000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16221000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7474000
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
834000
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
3999000
us-gaap Operating Expenses
OperatingExpenses
22375000
us-gaap Operating Expenses
OperatingExpenses
8831000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
3999000
us-gaap Operating Income Loss
OperatingIncomeLoss
22375000
us-gaap Operating Income Loss
OperatingIncomeLoss
8831000
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
10968000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-59000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-22316000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-19383000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
29000
us-gaap Net Income Loss
NetIncomeLoss
-22315000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
69771000
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
76562000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8443000
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
21000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-16057000
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
79902000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1279000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19276000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8131000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
5698000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
107000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
20000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-5805000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-20000
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
18826000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
30000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
11000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
161000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-56000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
18837000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-25137000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
10686000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
93360000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11257000
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
68223000
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21943000
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21919000
CY2020Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
24000
CY2019Q2 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
24000
etnb Issuance Of Common Stock Warrant In Connection With Term Loan Facility
IssuanceOfCommonStockWarrantInConnectionWithTermLoanFacility
634000
etnb Deferred Offering Costs Included In Accrued Expenses
DeferredOfferingCostsIncludedInAccruedExpenses
290000
etnb Deferred Offering Costs Included In Accrued Expenses
DeferredOfferingCostsIncludedInAccruedExpenses
204000
etnb Property And Equipment Purchases Included In Accounts Payable
PropertyAndEquipmentPurchasesIncludedInAccountsPayable
13000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying condensed consolidated financial statements include but are not limited to the fair value of stock options, the convertible preferred stock liability and certain accruals. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates. </p>
CY2020Q2 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
129000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
573000
CY2020Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
274000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
325000
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2019-06-28
etnb Reorganization Exchange Of Equity Percentage Of Common Stock Issued Upon Exchange
ReorganizationExchangeOfEquityPercentageOfCommonStockIssuedUponExchange
1.00
etnb Reorganization Exchange Of Equity Percentage Of Ordinary Shares Exchanged
ReorganizationExchangeOfEquityPercentageOfOrdinarySharesExchanged
1.00
CY2019Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.160849
CY2020Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
73900000
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0
etnb Capital Contributions Related To Extinguishment Of Preferred Stock Liability
CapitalContributionsRelatedToExtinguishmentOfPreferredStockLiability
25600000
us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
us-gaap:AccountingStandardsUpdate201813Member
CY2020Q2 us-gaap Change In Accounting Principle Accounting Standards Update Adopted
ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
true
CY2020Q2 us-gaap Change In Accounting Principle Accounting Standards Update Adoption Date
ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
2020-01-01
CY2020Q2 us-gaap Change In Accounting Principle Accounting Standards Update Immaterial Effect
ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
false
CY2019Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
0
CY2020Q2 etnb Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
1671000
CY2019Q4 etnb Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
2326000
CY2020Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1142000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1396000
CY2020Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
634000
CY2020Q2 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
232000
CY2020Q2 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
8000
CY2020Q2 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
369000
CY2020Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
87000
CY2019Q2 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
33000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
147000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
60000
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
910000
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
76000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1403000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
111000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1320243
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
549000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
11795
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
40482
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1816966
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
348601
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.34
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
30.19
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.62
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.87
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.44
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.03
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y2M23D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y3D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y5M12D
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
30353000
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
21218000
CY2020Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
6241000
CY2019Q4 etnb Capital Contribution Related To Extinguishment Of Preferred Stock Liability
CapitalContributionRelatedToExtinguishmentOfPreferredStockLiability
25600000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1816966
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7609671

Files In Submission

Name View Source Status
0001564590-20-040062-index-headers.html Edgar Link pending
0001564590-20-040062-index.html Edgar Link pending
0001564590-20-040062.txt Edgar Link pending
0001564590-20-040062-xbrl.zip Edgar Link pending
etnb-10q_20200630.htm Edgar Link pending
etnb-20200630.xml Edgar Link completed
etnb-20200630.xsd Edgar Link pending
etnb-20200630_cal.xml Edgar Link unprocessable
etnb-20200630_def.xml Edgar Link unprocessable
etnb-20200630_lab.xml Edgar Link unprocessable
etnb-20200630_pre.xml Edgar Link unprocessable
etnb-ex311_6.htm Edgar Link pending
etnb-ex312_9.htm Edgar Link pending
etnb-ex32_8.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending